Research conducted by TAmiRNA in collaboration with the Michael Ogon Laboratory (Orthopädisches Spital Speising) on microRNA-based biomarkers for the early detection of periprosthetic joint infections (PJI) was recently featured on Wien Heute, one of Austria’s most widely viewed regional television news programs (ORF, January 3, 2026). The coverage highlights both the clinical relevance of the problem and the translational potential of novel molecular diagnostic approaches.

Periprosthetic joint infections are among the most serious complications following hip and knee arthroplasty. Although the incidence is estimated at approximately 1-10%, PJIs are associated with substantial morbidity, prolonged treatment, and high healthcare costs. A major challenge in clinical practice remains the timely and reliable differentiation between infected and non-infected implants, particularly in early or low-grade infections.

The Wien Heute report presents the ongoing research efforts in Vienna that focus on analyzing synovial fluid for molecular biomarkers. At TAmiRNA, highly sensitive RNA analysis technologies such as next generation sequencing and RT-qPCR are applied to quantify short non-coding RNAs — microRNAs — that show characteristic changes in the presence of infection. These infection-associated microRNA patterns may provide additional, objective information to support clinical decision-making.

Synovial fluid obtained by joint aspiration is routinely collected during diagnostic work-up. Integrating molecular microRNA biomarkers into this workflow could enable earlier diagnosis and reduce diagnostic uncertainty. This is of particular importance, as delayed or inconclusive diagnosis often leads to suboptimal treatment strategies. Once bacterial biofilms have formed on implant surfaces, implant exchange is frequently unavoidable.

The research highlighted in the broadcast is ongoing, with initial results described as highly promising. These findings have already attracted attention in international orthopedic and scientific journals.

The long-term objective is to translate validated microRNA biomarker signatures into robust diagnostic tests that can be implemented in routine clinical practice, ultimately improving patient outcomes.